As we all know, outcomes are important to evaluating ROI; but while most solutions can provide some sort of data, not every data point carries the same weight. This often requires benefits teams and their advisor to dig a bit deeper to get the real story.

Drug prices for commercial health plans could increase under the recently passed Inflation Reduction Act. HR must act now to reduce costs.

The proposed changes would be particularly important for patients undergoing treatments that weaken the immune system, giving any dental infections the opportunity to spread.

The legislation would require the U.S. Secretary of Health and Human Services to negotiate directly with drug manufacturers over the price of some high-cost drugs in the Medicare program.